<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00941382</url>
  </required_header>
  <id_info>
    <org_study_id>OB Sil-02</org_study_id>
    <nct_id>NCT00941382</nct_id>
  </id_info>
  <brief_title>Sibutramine-metformin Combination Versus Sibutramine and Metformin Monotherapy in Obese Patients</brief_title>
  <official_title>Double-blind, Randomized Clinical Trial to Evaluate Effect of Combination Therapy of Metformin and Sibutramine Versus Metformin or Sibutramine Monotherapy Over Weight, Adiposity, Glucose Metabolism and Inflammatory State in Obese Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorios Silanes S.A. de C.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratorios Silanes S.A. de C.V.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the effect of sibutramine and metformin combination
      therapy in comparison with sibutramine or metformin monotherapy over weight, adiposity,
      glucose metabolism and inflammatory state in obese patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The treatment of obesity is strongly recommended because it exacerbates insulin resistance,
      hypertension, dyslipidemia and atherosclerosis, and represents a risk factor for type 2
      diabetes. Although diet and exercise are valuable in this treatment, patient compliance is a
      major problem. Sibutramine has been shown to be a highly effective pharmacotherapy for weigh
      loss in obese patients, mediated by increased satiety and an enhancement of energy
      expenditure. Metformin is widely used for glycemia control and is associated with a small to
      moderate body weight loss. We are assessing the combination of sibutramine and metformin, two
      agents with different mechanisms of action for control of body weight and metabolic
      dysregulation.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2008</start_date>
  <completion_date type="Anticipated">September 2009</completion_date>
  <primary_completion_date type="Anticipated">August 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>improvement of body weight, adiposity and inflammation state defined by serum adiponectin, leptin and C reactive protein</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>improvement of metabolic profile, defined by triglycerides, total cholesterol, HDL cholesterol, LDL cholesterol, insulin, and insulin sensitivity</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Sibutramin-Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sibutramine-metformin therapy in a single tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sibutramine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sibutramine monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin monotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sibutramine-Metformin</intervention_name>
    <description>sibutramine and metformin, 15 mg per day and 850 mg per day, respectively, in a single tablet, for 180 days</description>
    <arm_group_label>Sibutramin-Metformin</arm_group_label>
    <other_name>combination therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sibutramine</intervention_name>
    <description>15 mg per day for 180 days</description>
    <arm_group_label>Sibutramine</arm_group_label>
    <other_name>Sibutramine monohidrate Hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin 850 mg per day for 180 days</description>
    <arm_group_label>Metformin</arm_group_label>
    <other_name>Metformin Hydrochloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Age between 30 and 50 years

          -  Both genders

          -  BMI between 30 and 40

          -  Stable body weigh defined by over 5 per cent variability during the previous 3 months

          -  Fasting serum glucose less than 126 mg per dl

          -  Blood pressure over 140 and 90 mmHg

          -  Women ensuring contraceptive precautions.

          -  Communication and understanding capability.

          -  Informed consent awarding.

        Exclusion criteria

          -  Women were excluded if they were pregnant or lactating potential while no taking
             adequate contraceptive precautions

          -  Any smoking during the preceding 6 months

          -  No physical activity, defined by less than 15 minutes per day of walking

          -  Excessive physical activity equivalent to running over 60 minutes per day

          -  Known hypersensitivity to sibutramine or metformin

          -  Low commitment to follow the protocol statements

          -  Any investigational medication during the preceding 6 months

          -  Any drug or substance mayor toxicity exposure during the preceding 3 months

          -  Alcohol or any drug abuse during the previous 3 months

          -  Current medication of oral corticosteroids, anticoagulants, sympathomimetics,
             sympatholytics, lipid lowering drugs, any medication for type 2 diabetes, and any
             sibutramine interaction drug

          -  Current or previous evidence of ischemic heart disease, cardiac arrhythmia,
             cerebrovascular disease, chronic hepatic disease, two fold persistent elevation of
             ALT, AST or FA

          -  Carrying a pacemaker or any permanent bioelectronic component that could interfere
             with bioimpedance process

          -  Renal failure defined by serum creatinine equal or ever 1.2 mg per dL

          -  Not controlled thyroid disease defined by altered serum T3, T4 and TSH during the
             previous 3 months

          -  Hypertension

          -  Type 2 diabetes

          -  Anti-depressants, or any psychiatric disturbance treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jorge A González-Canudas, MD</last_name>
    <role>Study Director</role>
    <affiliation>Laboratorios Silanes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manuel González-Ortiz, PHD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Guadalajara</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ESperanza Martínez-Abundis, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Guadalajara</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centro Universitario de Ciencias de la Salud</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44340</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Cachofeiro V. Obesidad, Inflamación y disfunción endotelial. Rev Esp Obes 4: 194-204, 2006.</citation>
  </reference>
  <reference>
    <citation>Ferrannini E, Mari A. How to measure insulin sensitivity. J Hypertens. 1998 Jul;16(7):895-906. Review.</citation>
    <PMID>9794728</PMID>
  </reference>
  <reference>
    <citation>Lyle WG; Plastic Surgery Educational Foundation DATA Committee. Pharmacological treatment of obesity. Plast Reconstr Surg. 2002 Nov;110(6):1577-80.</citation>
    <PMID>12409783</PMID>
  </reference>
  <reference>
    <citation>Luque CA, Rey JA. The discovery and status of sibutramine as an anti-obesity drug. Eur J Pharmacol. 2002 Apr 12;440(2-3):119-28. Review.</citation>
    <PMID>12007530</PMID>
  </reference>
  <reference>
    <citation>Weigle DS. Pharmacological therapy of obesity: past, present, and future. J Clin Endocrinol Metab. 2003 Jun;88(6):2462-9. Review.</citation>
    <PMID>12788841</PMID>
  </reference>
  <reference>
    <citation>Hundal RS, Inzucchi SE. Metformin: new understandings, new uses. Drugs. 2003;63(18):1879-94. Review.</citation>
    <PMID>12930161</PMID>
  </reference>
  <reference>
    <citation>Bloomgarden ZT. Metformin. Diabetes Care. 1995 Jul;18(7):1078-80.</citation>
    <PMID>7555549</PMID>
  </reference>
  <reference>
    <citation>Campbell I. The obesity epidemic: can we turn the tide? Heart. 2003 May;89 Suppl 2:ii22-4; discussion ii35-7. Review.</citation>
    <PMID>12695431</PMID>
  </reference>
  <reference>
    <citation>McNulty SJ, Ur E, Williams G; Multicenter Sibutramine Study Group. A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. Diabetes Care. 2003 Jan;26(1):125-31.</citation>
    <PMID>12502668</PMID>
  </reference>
  <reference>
    <citation>Love-Osborne K, Sheeder J, Zeitler P. Addition of metformin to a lifestyle modification program in adolescents with insulin resistance. J Pediatr. 2008 Jun;152(6):817-22. doi: 10.1016/j.jpeds.2008.01.018. Epub 2008 Mar 19.</citation>
    <PMID>18492523</PMID>
  </reference>
  <reference>
    <citation>González-Ortiz M, Martínez-Abundis E, Mora-Martínez JM, Grover-Páez F. Renal handling of uric acid assessed by means of pharmacological tests in obese women. Diabetes Nutr Metab. 2001 Aug;14(4):189-94.</citation>
    <PMID>11716287</PMID>
  </reference>
  <reference>
    <citation>Clément K, Ferré P. Genetics and the pathophysiology of obesity. Pediatr Res. 2003 May;53(5):721-5. Epub 2003 Mar 5. Review.</citation>
    <PMID>12621112</PMID>
  </reference>
  <reference>
    <citation>Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA. 2002 Oct 9;288(14):1723-7.</citation>
    <PMID>12365955</PMID>
  </reference>
  <reference>
    <citation>Lozano Castañeda O. Adipocitoquinas. Rev Endocr Nutr. 10: 147-50, 2002.</citation>
  </reference>
  <reference>
    <citation>Karnehed N, Rasmussen F, Hemmingsson T, Tynelius P. Obesity and attained education: cohort study of more than 700,000 Swedish men. Obesity (Silver Spring). 2006 Aug;14(8):1421-8.</citation>
    <PMID>16988085</PMID>
  </reference>
  <reference>
    <citation>Hensrud DD, Klein S. Extreme obesity: a new medical crisis in the United States. Mayo Clin Proc. 2006 Oct;81(10 Suppl):S5-10. Review.</citation>
    <PMID>17036573</PMID>
  </reference>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 14, 2009</study_first_submitted>
  <study_first_submitted_qc>July 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2009</study_first_posted>
  <last_update_submitted>July 15, 2009</last_update_submitted>
  <last_update_submitted_qc>July 15, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 17, 2009</last_update_posted>
  <responsible_party>
    <name_title>Jorge González Canudas</name_title>
    <organization>Laboratorios Silanes S.A. de C.V.</organization>
  </responsible_party>
  <keyword>sibutramine</keyword>
  <keyword>metformin</keyword>
  <keyword>obesity</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Sibutramine</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>July 29, 2011</submitted>
    <returned>August 29, 2011</returned>
    <submitted>September 2, 2011</submitted>
    <returned>October 5, 2011</returned>
    <submitted>February 27, 2012</submitted>
    <returned>March 27, 2012</returned>
    <submitted>July 20, 2012</submitted>
    <returned>August 22, 2012</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

